Ocular Oncology and Pathology最新文献

{"title":"Description and Characteristics of Ocular Tumor Lysis Syndrome.","authors":"Talisa E de Carlo Forest, Scott C N Oliver","doi":"10.1159/000538761","DOIUrl":"10.1159/000538761","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to describe and evaluate characteristics of ocular tumor lysis syndrome (OTLS) in eyes with uveal melanoma.</p><p><strong>Methods: </strong>Retrospective chart review of all patients with OTLS at the University of Colorado from 2009 to 2021. Data collected included patient demographics, tumor characteristics, radiation dosimetry, gene expression profiling (GEP), OTLS characteristics, management, and outcomes.</p><p><strong>Results: </strong>Seven eyes of seven patients with uveal melanoma treated with I-125 brachytherapy developed OTLS. Average age was 59 years (range 32-83). Mean apical height was 8.6 mm (range 6-11); mean diameter was 12.7 mm (range 8.5-15.3). All tumors were treated with plaques ≥16 mm in diameter. On presentation, 5/7 tumors had subretinal fluid, and 6/7 had collar-button configuration. OTLS presented as extensive pigment dispersion in the vitreous in all eyes, subretinal pigment and/or retinal detachment in 4/7 eyes, vitreous hemorrhage in 2/7 eyes, and anterior chamber pigment in 3/7 eyes. Four tumors were GEP class 1, two were class 2, and one was unclassified. Biopsy route was trans-scleral in 4/7 eyes and trans-vitreal in 3/7 eyes. OTLS occurred 2-4 weeks after an intraocular procedure in 5/7 eyes. All underwent pars plana vitrectomy. Cytology of the vitreous, obtained in five cases, showed pigment laden macrophages and hemorrhage, but only 1/5 eyes had viable malignant cells. Four eyes were stable at the last follow-up, two were enucleated, and one had no light perception from pigmentary glaucoma. Poor vision (<20/200) occurred in 6/7 cases. Three patients died from metastasis (tumors were GEP class 2, GEP class without subclassification, and no GEP classification performed).</p><p><strong>Conclusions: </strong>OTLS is a rare but devastating complication of uveal melanoma. Common characteristics included large plaque diameter, presence of subretinal fluid, and collar-button shape. The extensively dispersed pigment is typically not malignant. Though poor vision is common, enucleation may be avoided in most eyes through vitreoretinal surgical repair.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"139-145"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ruthenium-106 Plaque Brachytherapy for Circumscribed Choroidal Hemangioma: A Case Series and Review of Literature.","authors":"Islam Y Swaify, Hany Hamza, Ayman M Khattab, Mohamed-Sameh H El-Agha, Mostafa A El-Helw, Tamer A Macky, Dina H Hassanein, Shaymaa H Salah, Abdussalam M Abdullatif, Alia M Noureldine, Yasmine A Meqdad, Salma F Al-Etr, Layla El Qadi, Alaa E Fayed","doi":"10.1159/000539384","DOIUrl":"10.1159/000539384","url":null,"abstract":"<p><strong>Introduction: </strong>We aim to report the anatomical and functional outcomes of ruthenium-106 brachytherapy in the management of circumscribed choroidal hemangiomas (CCH).</p><p><strong>Methods: </strong>This is a single-center, retrospective case series including patients with unilateral symptomatic CCH treated with ruthenium-106 brachytherapy at the Cairo University Ocular Oncology Service. Patient records were analyzed for patients' demographics, best corrected visual acuity (BCVA), tumor dimensions (thickness and largest base diameter), foveal subretinal fluid, radiation-related complications, and recurrence.</p><p><strong>Results: </strong>Seven patients were included in the study (including 6 males) with a mean age of 39.3 ± 15.4 years; ruthenium-106 plaque was used to deliver 50 Gray to the tumor apex. After a mean follow-up duration of 12.5 months, all patients had significant improvement in BCVA after treatment, mean tumor height decreased significantly from 4.76 ± 1.76 mm to 1.70 ± 1.2 mm (<i>p</i> value 0.01). The largest tumor base diameter also decreased significantly from 9.13 ± 2.68 mm to 4.65 ± 3.75 mm (<i>p</i> value 0.05). Subretinal fluid and exudative retinal detachment resolved in all patients, and no significant radiation-related complications were observed in any patient. None of the patients needed any further treatment or experienced recurrence within the follow-up period.</p><p><strong>Conclusion: </strong>Ruthenium-106 brachytherapy is an effective tool in the management of symptomatic CCH with a good visual prognosis and safety profile.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"146-153"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368397/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Much Time Do Focal Treatments for Retinoblastoma Add to Anesthetic Exposure?","authors":"David H Abramson, Jacquelyn Gaccione, Christina Bracken, Todd Liu, Edith Guarini, Andrea Bobin, Angela Foerch, Melissa A Robbins, Ricardo Dodds Rojas, Jasmine H Francis","doi":"10.1159/000539488","DOIUrl":"10.1159/000539488","url":null,"abstract":"<p><strong>Introduction: </strong>Children with retinoblastoma have anesthesia for exams and treatment, but there is little information about how long treatment interventions (laser, cryotherapy, and intravitreal injections) add to routine exams under anesthesia (EUA). This information would be useful for planning operating room schedules, staff schedules, family expectations, and billing.</p><p><strong>Methods: </strong>A retrospective, single-center, Institutional Review Board (IRB) approved review of anesthesia duration for retinoblastoma children undergoing EUA with laser, cryotherapy, or intravitreal injections performed at MSK between January 2019 and November 2023.</p><p><strong>Results: </strong>Three hundred eight patients had 2,399 EUAs. The average EUA lasted 24.3 min (range 7-77 min) when no interventions were done. Laser photocoagulation added an average of 18.9 min (range 19-77 min), cryotherapy 26.1 min (range 27-75 min), and intravitreal injection 23.5 min (range 10-71 min) to the basic EUA time. Bilateral laser treatments took 8 min longer than unilateral treatments.</p><p><strong>Conclusion: </strong>EUAs for children with retinoblastoma can be performed relatively quickly. Interventions such as laser, cryotherapy, or intravitreal injections roughly double the time under anesthesia but in some cases can take much longer (>1 h).</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"182-188"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368391/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis.","authors":"Tatsuya Yunoki, Akio Miyakoshi, Atsushi Hayashi","doi":"10.1159/000538537","DOIUrl":"10.1159/000538537","url":null,"abstract":"<p><strong>Introduction: </strong>The aim of the study was to evaluate the clinicopathological features of eyelid sebaceous gland carcinoma (SGC), which requires immunohistochemical examination for a definitive diagnosis.</p><p><strong>Methods: </strong>Twenty-seven patients with a final diagnosis of eyelid SGC at Toyama University Hospital between April 2016 and April 2022 were retrospectively studied. In cases with a strong clinical suspicion of SGC, if the initial pathological diagnosis by hematoxylin-eosin staining was non-SGC, additional detailed pathology was performed, including immunostaining for adipophilin (ADP) and androgen receptor (AR).</p><p><strong>Results: </strong>Five patients (18.5%) had a diagnosis other than SGC, including three with squamous cell carcinoma (SCC), one with basal cell carcinoma, and one with Bowen disease. In these 5 cases, detailed pathology, including immunostaining for ADP and AR, was performed again, which ultimately led to the diagnosis of SGC. ADP was positive in all 5 cases, and AR was positive in 4 cases. The 3 patients diagnosed with SCC were characterized by a high Ki-67 index, active mitosis, and relatively low differentiation.</p><p><strong>Conclusion: </strong>SGC can be pathologically diagnosed in other cancers, such as SCC and BCC. When SCC was diagnosed, it was often hypo-differentiated and required more attention. Immunostaining for ADP and AR is invaluable for confirming SGC diagnosis.</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 3","pages":"131-138"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368396/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142120351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum.","authors":"","doi":"10.1159/000537728","DOIUrl":"https://doi.org/10.1159/000537728","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1159/000533308.].</p>","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"10 1","pages":"63"},"PeriodicalIF":0.9,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11937980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143720609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Periocular Sebaceous Carcinoma: case audit from the National Specialist Ophthalmic Pathology Service in Liverpool from 2009 to 2022, to assess the diagnostic utility of PRAME expression.","authors":"Amizatul Aini Salleh, Y. Krishna, Sarah E. Coupland","doi":"10.1159/000535169","DOIUrl":"https://doi.org/10.1159/000535169","url":null,"abstract":"Introduction: Periocular sebaceous carcinoma (PSC) remains a common diagnostic pitfall both clinically and histomorphologically. PRAME (PReferentially Expressed Antigen in MElanoma) has been studied in the various neoplasms as proposed as diagnostic and therapeutic markers. PRAME is expressed in normal sebaceous units and in some sebaceous lesions; however, its utility in sebaceous carcinoma diagnosis has not yet been extensively investigated. \u0000We conducted a 13-year retrospective review of the patients diagnosed with PSC at the National Specialist Ophthalmic Pathology Service in Liverpool. Herein, we report the histomorphological and immunohistochemical (IHC) features of these tumors, particularly PRAME expression in this cohort.\u0000\u0000Methods: Thirty-one PSC cases diagnosed between 2009 to 2022 were retrieved from the histopathology archives. Twenty cases diagnosed as invasive PSC and 11 cases with in-situ PSC were included. The hematoxylin and eosin (H&E) slides and previously-performed IHC slides were reviewed; clinical information data were obtained. Cases with an adequate tissue were also stained for PRAME (PReferentially expressed Antigen in MElanoma) and adipophilin (if not already performed). \u0000\u0000Results: In total, there were 24 females and 7 males diagnosed with PSC, ranging from 55 to 90 years (median, 78 years). The types of specimens received were: 11 conjunctival mapping biopsies, 19 excisions/wedge resections, and 1 orbital exenteration. The eyelid was the commonest site involved (n=24), followed by eyelid with conjunctiva (3), and conjunctiva alone (4). All patients presented with the clinical suspicion of malignancy. \u0000Histologically, 11 invasive PSC (55%) exhibited poorly differentiated morphology, composed of predominantly atypical basaloid cells with minimal sebocytic differentiation; 9 cases (45%) were moderately-differentiated with noticeable finely multivacuolated cytoplasm; and 3 (15%) showed associated comedo-necrosis. Most invasive PSC showed moderate to brisk mitotic activities. \u0000Of those cases with available immunostains (n=31), 25 (80.6%) expressed adipophilin; 18 (58.1%) Ber-EP4; 14 (45.2%) epithelial membrane antigen (EMA); and 5 (16.1%) both androgen receptor and perforin positivity. PRAME expression was seen in normal sebaceous glands; however, only (5/19; 26%) of invasive PSC showed focal weak-to-moderate PRAME positivity, and mostly in moderately-differentiated tumors. None of the in-situ PSC were PRAME positive. \u0000\u0000Conclusions: Most PSC are moderate- to poorly-differentiated. Although PRAME is expressed in normal sebaceous units, it appears less useful as diagnostic marker for PSC, especially in poorly-differentiated tumors. In difficult cases, panels of immunohistochemical studies (Adipophilin, Ber-EP4 and EMA) achieve a definitive diagnosis.","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"128 ","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138982228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ocular dirofilariasis: a clinicopathologic case series and literature review","authors":"Matthew Camacho, Michael Antonietti, Yoseph Sayegh, Jordan D. Colson, Anne L. Kunkler, Kevin D. Clauss, Hannah Muniz-Castro, Wendy W. Lee, Sonia H. Yoo, Thomas E. Johnson, Sander R. Dubovy","doi":"10.1159/000533340","DOIUrl":"https://doi.org/10.1159/000533340","url":null,"abstract":"Abstract \u0000Purpose\u0000Ocular dirofilariasis is an uncommon zoonotic infection that is usually associated with a carnivore host. In this case series and literature review we investigate the clinical presentation, management, and histopathology of ocular dirofilariasis. \u0000Methods\u0000The database at the Florida Lions Ocular Pathology Laboratory was searched for surgical specimens at the Bascom Palmer Eye Institute under approval of the institutional review board. Patients with a histopathologic diagnosis of dirofilariasis between the years of 1962 and 2022 from the Florida Lions Ocular Pathology laboratory database were included (n=3). \u0000A systematic Pubmed search was conducted by two independent authors to identify published cases of ophthalmic dirofilariasis worldwide. Keywords were used to identify articles and exclusion criteria were applied. \u0000Results\u0000Three patients, two males and one female, were identified from the Florida Lions Ocular Pathology database with a diagnosis of ocular dirofilariasis. The mean age was 46.7 years (with a range 33-57 years). There were two eyelid lesions (Cases 1 and 3) and one involving the subconjunctival space (Case 2). All three organisms were excised and presumptively identified as Dirofilaria tenuis. All three patients were managed with curative surgical removal and recovered completely. \u0000Our review of the literature identified 540 published reports with 142 published reports with 186 cases met the exclusion criteria.\u0000Conclusion\u0000We present a case series and literature review of ocular dirofilariasis. Knowledge of the incidence, risk factors, prevention and diagnosis of this unique parasitic infection will help in proper management and prevent further ocular complications.","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"85 1","pages":""},"PeriodicalIF":1.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139010729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents Vol. 9, 2023","authors":"Arun D. Singh, H. Grossniklaus","doi":"10.1159/issn.2296-4657","DOIUrl":"https://doi.org/10.1159/issn.2296-4657","url":null,"abstract":"","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"396 2","pages":"I - IV"},"PeriodicalIF":1.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138993730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Value of the International Classification of Diseases, 9th Revision Codes for Identifying Ocular Oncology Diagnoses","authors":"Kenny Y. Wang, Timothy T. Xu, Launia J. White, Lauren A. Dalvin","doi":"10.1159/000534688","DOIUrl":"https://doi.org/10.1159/000534688","url":null,"abstract":"Introduction: To determine the predictive value of International Classification of Diseases, 9th Revision (ICD-9) billing codes for identifying ocular oncology diagnoses. Methods: Population-based retrospective cohort study of all Olmsted County, Minnesota residents with any ocular neoplasm-related ICD-9 code from January 1, 2006 to October 1, 2015. All medical records were reviewed for confirmation of ocular neoplasm. Diagnoses with ≥5 cases confirmed via medical record review were compared to corresponding ICD-9 codes. Main outcome measures included positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity of ICD-9 codes. Results: Among 3,932 subjects with ≥1 ocular neoplasm-related ICD-9 code, 21 diagnoses met study criteria. The most frequent intraocular, extraocular/orbital, and ocular surface diagnoses were choroidal nevus (n=824), epidermal inclusion cyst (n=263), and conjunctival nevus (n=74), respectively. PPVs ranged from 1.2% to 73.8%, NPVs from 96.9% to 100%, sensitivity from 0% to 100%, and specificity from 85.7% to 100%. Among malignant neoplasms, PPV ranged from 0% to 73.8%: ocular surface squamous neoplasia (PPV: 0%), choroidal melanoma (PPV: 25.0%), eyelid squamous cell carcinoma (PPV: 46.7%), and eyelid basal cell carcinoma (PPV: 73.8%). Among benign neoplasms, PPV ranged from 1.2% (dermoid cyst) to 61.6% (choroidal nevus). Conclusion: There was wide variation in predictive value of ocular neoplasm-related ICD-9 billing codes, which suggests that ocular oncology-related claims data alone may overestimate the true number of ocular oncology diagnoses.","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134907523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sympathetic ophthalmia in patients with enucleation or evisceration: pathology laboratory and IRIS® Registry experience","authors":"Khanh Bui, Maurizio Tomaiolo, Kaylene Carter, Codrin Iacob, Vamsee Neerukonda, Anna Stagner, Zaynab Sajjadi, Katherine V. Escobar, Paula Ordoñez Armijos, Ralph C. Eagle, Sonia Mehta, James P. Dunn, Leslie Hyman, Tatyana Milman","doi":"10.1159/000533310","DOIUrl":"https://doi.org/10.1159/000533310","url":null,"abstract":"Introduction: Sympathetic ophthalmia (SO) is a rare bilateral granulomatous panuveitis that can follow surgical or non-surgical ocular trauma in one eye. Because its diagnosis requires clinical-pathologic correlation, the true incidence of SO is unknown, and there is a need to understand the recent trends in risk factors and frequency of this condition. Methods: Pathology records of all enucleated or eviscerated (ENEV) eyes at three pathology laboratories were reviewed. Data collected included patient demographics, procedure indication, pathology diagnosis, and clinical history of trauma and uveitis. IRIS® Registry (Intelligent Research in Sight) was searched for all patients with SO, acquired absence of eye (AAE), and/or ENEV. Data obtained included patient demographics, ocular procedures, and preoperative diagnoses within 30 days of AAE/ENEV. Results: In the pathology laboratory setting, the incidence of SO over a 36-year period in patients who underwent ENEV was 0.2% (20/9,092); the 5-year incidence ranged from 0.0-0.3%. Among the 20 eyes with SO, the inciting event was surgical trauma in 50% (10/20), non-surgical trauma in 45% (9/20), and missing/undetermined in 5% (1/20). SO was suspected pre-operatively in 7/20 (35%) patients. Clinical concern for SO and ruptured globe were indications for ENEV in 50/9,092 (0.5%) and 872/9,092 (10%) patients, respectively. In the IRIS Registry, 0.7% (199/27,830) of patients with AAE/ENEV had diagnosis of SO. The frequency of SO between 2015-2020 was 0.01% (7,371/62,318,249); of these 7,371 cases, 199 (3%) had AAE/ENEV. In 25,975 patients with available data, injury and SO were listed as diagnoses less than 30 days prior to AAE/ENEV in 909 (4%) and 63 (0.2%) cases, respectively. Discussion/Conclusion: The frequency of SO in recent decades is low. Most cases of SO are not managed with eye removal. In histopathology-confirmed SO, surgical trauma is as frequent as non-surgical trauma as an inciting etiology of disease.","PeriodicalId":19434,"journal":{"name":"Ocular Oncology and Pathology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135646428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}